300 related articles for article (PubMed ID: 35565264)
1. Immunotherapy for HER2-Positive Breast Cancer: Clinical Evidence and Future Perspectives.
Agostinetto E; Montemurro F; Puglisi F; Criscitiello C; Bianchini G; Del Mastro L; Introna M; Tondini C; Santoro A; Zambelli A
Cancers (Basel); 2022 Apr; 14(9):. PubMed ID: 35565264
[TBL] [Abstract][Full Text] [Related]
2. Immunotherapy for HER2-positive breast cancer: recent advances and combination therapeutic approaches.
Ayoub NM; Al-Shami KM; Yaghan RJ
Breast Cancer (Dove Med Press); 2019; 11():53-69. PubMed ID: 30697064
[TBL] [Abstract][Full Text] [Related]
3. Emerging Targeted Therapies for HER2-Positive Breast Cancer.
Mercogliano MF; Bruni S; Mauro FL; Schillaci R
Cancers (Basel); 2023 Mar; 15(7):. PubMed ID: 37046648
[TBL] [Abstract][Full Text] [Related]
4. Progress and Prospect of Immunotherapy for Triple-Negative Breast Cancer.
Luo C; Wang P; He S; Zhu J; Shi Y; Wang J
Front Oncol; 2022; 12():919072. PubMed ID: 35795050
[TBL] [Abstract][Full Text] [Related]
5. Immunotherapies against HER2-Positive Breast Cancer.
Duro-Sánchez S; Alonso MR; Arribas J
Cancers (Basel); 2023 Feb; 15(4):. PubMed ID: 36831412
[TBL] [Abstract][Full Text] [Related]
6. Combination of HER2-targeted agents with immune checkpoint inhibitors in the treatment of HER2-positive breast cancer.
Matusz-Fisher A; Tan AR
Expert Opin Biol Ther; 2022 Mar; 22(3):385-395. PubMed ID: 34806498
[TBL] [Abstract][Full Text] [Related]
7. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
Martin M; López-Tarruella S
Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
[TBL] [Abstract][Full Text] [Related]
8. Immunotherapy in HER2-positive breast cancer: state of the art and future perspectives.
Krasniqi E; Barchiesi G; Pizzuti L; Mazzotta M; Venuti A; Maugeri-Saccà M; Sanguineti G; Massimiani G; Sergi D; Carpano S; Marchetti P; Tomao S; Gamucci T; De Maria R; Tomao F; Natoli C; Tinari N; Ciliberto G; Barba M; Vici P
J Hematol Oncol; 2019 Oct; 12(1):111. PubMed ID: 31665051
[TBL] [Abstract][Full Text] [Related]
9. Immunotherapy in triple-negative breast cancer: Insights into tumor immune landscape and therapeutic opportunities.
Ribeiro R; Carvalho MJ; Goncalves J; Moreira JN
Front Mol Biosci; 2022; 9():903065. PubMed ID: 36060249
[TBL] [Abstract][Full Text] [Related]
10. HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development.
Arab A; Yazdian-Robati R; Behravan J
Arch Immunol Ther Exp (Warsz); 2020 Jan; 68(1):2. PubMed ID: 31915932
[TBL] [Abstract][Full Text] [Related]
11. Clinical development of immunotherapies for HER2
Costa RLB; Czerniecki BJ
NPJ Breast Cancer; 2020; 6():10. PubMed ID: 32195333
[TBL] [Abstract][Full Text] [Related]
12. Current Immunotherapy Treatments of Primary Breast Cancer Subtypes.
Brown SR; Vomhof-DeKrey EE
Biomedicines; 2024 Apr; 12(4):. PubMed ID: 38672249
[TBL] [Abstract][Full Text] [Related]
13. Clinical trial data and emerging immunotherapeutic strategies: hormone receptor-positive, HER2- negative breast cancer.
Kearney MR; McGuinness JE; Kalinsky K
Breast Cancer Res Treat; 2021 Aug; 189(1):1-13. PubMed ID: 34213658
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy as a partner for HER2-directed therapies.
Clifton GT; Peoples AGE
Expert Rev Anticancer Ther; 2021 Jul; 21(7):739-746. PubMed ID: 33666116
[No Abstract] [Full Text] [Related]
15. Immunotherapy in Breast Cancer: When, How, and What Challenges?
Henriques B; Mendes F; Martins D
Biomedicines; 2021 Nov; 9(11):. PubMed ID: 34829916
[TBL] [Abstract][Full Text] [Related]
16. The evolving therapeutic landscape of trastuzumab-drug conjugates: Future perspectives beyond HER2-positive breast cancer.
von Arx C; De Placido P; Caltavituro A; Di Rienzo R; Buonaiuto R; De Laurentiis M; Arpino G; Puglisi F; Giuliano M; Del Mastro L
Cancer Treat Rev; 2023 Feb; 113():102500. PubMed ID: 36587473
[TBL] [Abstract][Full Text] [Related]
17. Targeted Therapeutic Options and Future Perspectives for HER2-Positive Breast Cancer.
Ferrando-Díez A; Felip E; Pous A; Bergamino Sirven M; Margelí M
Cancers (Basel); 2022 Jul; 14(14):. PubMed ID: 35884366
[TBL] [Abstract][Full Text] [Related]
18. Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.
Torres ETR; Emens LA
Breast Cancer Res Treat; 2022 Jan; 191(2):291-302. PubMed ID: 34716871
[TBL] [Abstract][Full Text] [Related]
19. Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects.
Jia H; Truica CI; Wang B; Wang Y; Ren X; Harvey HA; Song J; Yang JM
Drug Resist Updat; 2017 May; 32():1-15. PubMed ID: 29145974
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy in breast cancer: an overview of current strategies and perspectives.
Debien V; De Caluwé A; Wang X; Piccart-Gebhart M; Tuohy VK; Romano E; Buisseret L
NPJ Breast Cancer; 2023 Feb; 9(1):7. PubMed ID: 36781869
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
